Defense Advanced Research Projects AgencyTagged Content List


The identification and transformation of substances

Showing 10 results for Chemistry + Programs RSS
Efficient discovery and production of new molecules is essential to realize capabilities across the DoD, from simulants and medicines essential to counter emerging threats, to coatings, dyes and specialty fuels needed for advanced performance.
Destroying bulk stores of chemical warfare agents (CWAs) and organic precursors is a significant challenge for the international community. Today, for example, there are no approaches that exploit chemistries that are truly agnostic in terms of the agents that can be processed. In addition, current approaches require transport of agents from the storage site to a neutralization site. Ensuring safe transport of the agent can add significant cost and time to the process.
The BioFuels program seeks to develop renewable jet fuel (JP-8) for military aviation that meets or exceeds JP-8 performance metrics to help reduce the military’s dependence on traditional petroleum-derived fuels. These renewable fuels are derived from cellulosic materials and algal species that don’t compete with consumable food crops. The cellulosic material conversion process aims to demonstrate technology to enable 50% energy conversion efficiency in the conversion of cellulosic material feedstock to JP-8.
The Biostasis program aims to extend the time for lifesaving medical treatment, often referred to as “the Golden Hour,” following traumatic injury or acute infection, thus increasing survivability for military personnel operating in far-forward conditions with limited access to medical professionals or trauma centers. To do so, Biostasis is developing novel chemical biology approaches that reversibly and controllably slow biological systems without cold-chain to stabilize and protect their functional capacity until medical intervention is possible.
Health threats often evolve more quickly than health solutions. Despite ongoing research in the government and the biopharmaceutical industry to identify new therapies, the Department of Defense (DoD) currently lacks tools to address the full spectrum of chemical, biological, and disease threats that could impact the readiness of U.S. forces.